舒利迭与布地奈德气雾吸入治疗对中重度支气管哮喘患者肺功能及免疫功能的影响  

Influence of seretide and budesonide on immune function and pulmonary function in patients with moderate and severe bronchial asthma

作　　者：兰丽敏 Lan Limin(Department of Pharmacy,Yantai Mountain Hospital,Yantai 264000,China)

机构地区：[1]烟台市烟台山医院药剂科,264000

出　　处：《国际医药卫生导报》2018年第22期3477-3480,共4页International Medicine and Health Guidance News

摘　　要：目的探讨舒利迭与布地奈德气雾吸入治疗对中重度支气管哮喘患者肺功能及免疫功能的影响.方法选取本院2016年5月至2017年9月收治的120例中重度支气管哮喘患者进行研究,按随机数字表法将其分为研究组与对照组,各60例.对照组采用布地奈德气雾吸入治疗,研究组采用舒利迭治疗,治疗后比较两组患者治疗效果、肺功能及免疫功能改善情况、不良反应发生情况.结果研究组治疗总有效率95.00%高于对照组76.67%,差异有统计学意义（P 〈0.05）;治疗前,肺功能及免疫功能组间比较,差异无统计学意义（P 〉0.05）;治疗后,研究组FEV1、FVC、PEF肺功能指标分别为（1.82±0.39）L、（2.76±0.37） L 、（277.87±56.57） L/mm,均高于对照组（1.53±0.51） L,（2.51±0.23） L,（251.59±54.30） L/mm,差异均有统计学意义（均P 〈0.05）;治疗后,研究组CD3＋、CD4＋、CD4＋/CD8＋免疫功能分别为（63.05±3.64）%、（38.93±3.15）% 、（1.61±0.43）,均高于对照组（57.92±3.96）%,（35.06±3.28）%,（1.32±0.37）,差异均有统计学意义（均P 〈0.05）.结论舒利迭对中重度支气管哮喘患者肺功能及免疫功能改善作用优于布地奈德气雾吸入治疗,临床疗效及安全性好.Objective To investigate the infuence of seretide and budesonide on immune function and pulmonary function in patients with moderate to severe bronchial asthma. Methods 120 patients with moderate to severe bronchial asthma were chosen as experimental objects, and were divided into a control group and a research group. The control group were treated with budesonide, and the research group with seretide. After the treatment, the clinical effects, immune function, pulmonary function, and adverse reactions were compared between two group. Results The total effective rate of the research group was higher than that of the control group （95.00% vs. 96.67%）, with a statistical difference （P〈0.05）. There were statistical differences in pulmonary function and immune function between groups before the treatment （P〉0.05）. After the treatment, the FEV1 [（1.82±0.39）L vs. （1.53±0.51）L], FVC[（2.76±0.37）L vs. （2.51±0.23）L], and PEF [（277.87±56.57）L/mm vs. （251.59±54.30）L/mm] were higher in the research group than in the control group （P〈0.05）. After the treatment, CD3＋ [（63.05±3.64）% vs. （57.92±3.96）%], CD4＋ [（38.93±3.15）% vs. （35.06±3.28）%], and CD4＋/CD8＋ [ （1.61±0.43） vs. （1.32±0.37）] were higher in the research group than in the control group （P 〈 0.05）. There was no statistical difference in the incidence of adverse reactions between the two groups （P 〉 0.05）. Conclusions Seretide is superior to Budesonide aerosol inhalation in the treatment of moderate and severe bronchial asthma, and has better clinical effcacy and safety.

关 键 词：支气管哮喘 布地奈德 舒利迭 免疫功能 肺功能 

分 类 号：R562.25[医药卫生—呼吸系统]